Cardinal Health (CAH) Q1 2027 earnings review
Cardinal Health raises its profit plan and renews CVS deal
Cardinal Health, the drug and medical-supply distributor, grew profit much faster than sales while locking in its largest customer. First-quarter revenue rose 5% to $67.5 billion, and profit per share excluding one-offs climbed 28% on higher-margin specialty drugs, lower taxes and $500 million of share buybacks. Chief executive Jason Hollar raised the full-year profit outlook, though by our math the plan still has per-share growth slowing to about 15% over the rest of the year as recent acquisitions are lapped.
| Revenue | $67.5B +5% from a year ago |
|---|---|
| Profit per share, excluding one-offs | $3.26 +28% from a year ago |
| Pharmaceutical segment profit | $783M +17% from a year ago |
| Full-year profit per share outlook | Raised $0.40 middle of the range: 18% growth ex-tariff refund |
⚖️ Verdict: 🟢 Bullish
The story got better because Cardinal Health signed a binding letter of intent to renew its drug distribution contracts with CVS Health, taking a 28%-of-revenue risk off the table, and raised its pharmaceutical profit plan. One caution: the gap between reported and adjusted profit widened as ongoing pay for doctors at acquired clinics hit $94 million, and the smaller growth units still grew revenue by only 7.5%.
The question now is whether the specialty and home-health units can keep expanding margins on their own once last year's doctor-practice acquisitions pass their one-year mark next quarter. Either existing customers keep driving double-digit profit growth, or the pace slows toward single digits without new deals. Second-quarter pharmaceutical profit and home-health revenue will tell.
🐂 Bull Case
Specialty Drugs and Generics Lift the Core Margin
Cardinal Health makes most of its money in Pharmaceutical and Specialty Solutions, the unit that delivers branded, generic and complex specialty medicines to pharmacies and clinics. Specialty drugs and doctor-office management services carry higher margins than standard drug wholesaling, so the distributor wants them to grow faster than the rest of the unit.
First-quarter division sales rose 6% from a year ago to $62.6 billion on "brand and specialty pharmaceutical sales growth from existing customers", the company said. Segment profit climbed 17% to $783 million on "contributions from brand and specialty products and positive generics program performance".
Company-wide gross margin expanded by 0.22 percentage points as the cost of products sold fell to 96.15% of revenue from 96.38%. Because the division beat its early pace, chief executive Jason Hollar raised its full-year profit growth outlook to a range of 10% to 12%, up from 8% to 11%.
What to watch: second-quarter pharmaceutical profit growth, when Cardinal Health laps last November's purchase of Solaris Health, a network of urology doctor practices. Holding profit growth near 9% — the pace implied by the full-year outlook for the rest of the year — would show that existing customers, not just acquisitions, are driving the margin gain.
CVS Letter of Intent Removes the Biggest Customer Risk
Pharmacy chain CVS Health is Cardinal Health's largest customer, accounting for 28% of total revenue last fiscal year. Investors had worried about the upcoming renewal of that contract after losing another big pharmacy account, OptumRx, two years ago.
This quarter Cardinal Health announced it was "entering into a binding letter of intent to renew its pharmaceutical distribution agreements with CVS Health". The drug wholesaler also raised its full-year pharmaceutical profit outlook at the same time.
Locking in the agreement removes the threat of a sudden volume hole in the core distribution network, and the raised profit plan indicates that the renewal did not require an immediate price cut.
What to watch: the length of the final contract and any commentary on fee terms when Cardinal Health files its quarterly report. A multi-year term without margin givebacks in fiscal 2028 would settle the customer concentration debate.
Fast Buybacks and Lower Taxes Boost the Raised Outlook
“Given this quarter's strong performance and our updated expectations for the remainder of the year, we are raising our fiscal 2027 non-GAAP EPS outlook,” chief executive Jason Hollar said. Cardinal Health lifted its full-year target by $0.40 per share, to between $12.80 and $13.00.
Operational gains only explain part of the increase. The healthcare group generated $1.58 billion of free cash flow excluding one-offs, up 23% from a year ago, and spent $500 million to finish its baseline share buyback in the first quarter alone.
That early buyback lowered the expected full-year diluted share count to between 231 million and 232 million, down from about 233 million. Management also cut the expected tax rate excluding one-offs by half a percentage point, to between 18.5% and 19.5%, so fewer shares and lower taxes carry a meaningful slice of the per-share raise.
What to watch: additional share repurchases over the next three quarters under the $6.4 billion board authorization. More buybacks would push the share count below 231 million and add further support to per-share profit.
🐻 Bear Case
Doctor Practice Pay Widens the Gap to Reported Profit
Cardinal Health highlights profit excluding one-offs, which rose 28% to $3.26 per share this quarter, ahead of the 27% rise in standard accounting profit to $2.38 per share. The gap between the two measures widened to $0.88 per share, up from $0.67 a year ago.
- Amortization and acquisition costs: $182 million pre-tax, up from $104 million a year ago
- Physician practice compensation: $94 million pre-tax, up from $64 million a year ago
- Distribution and administrative expenses: 2.36% of revenue, up 0.08 percentage points
The company strips out "contingency cash payments or the issuance of share-based payment awards, which include service requirements, as a part of certain physician practice acquisitions". Because doctors must stay on the job to earn those payouts, the $94 million is an ongoing staffing cost of running the acquired clinics, not a one-time deal fee.
What to watch: the quarterly charge for acquisition-related compensation in the second quarter, once Solaris Health has been owned for a full year. A number that stays near $90 million would show the cost is permanent.
Smaller Growth Units Still Need a Second-Half Jump
Cardinal Health groups its three faster-growing units — Nuclear and Precision Health Solutions (radioactive medicines for imaging and cancer therapy), at-Home Solutions (medical supplies shipped to patients' homes) and OptiFreight Logistics (hospital shipping management) — into the Other segment. The company relies on these units, which earn an 11% profit margin, to lift overall profitability.
First-quarter revenue in the group rose 7.5% from a year ago to $1.76 billion, while profit climbed 16% to $193 million. Even so, Cardinal Health raised its full-year revenue growth plan for the segment to between 12% and 14%, up from 11% to 13%.
Since passing the one-year mark of the Advanced Diabetes Supply acquisition in the fourth quarter, top-line growth has sat near 7% for two straight quarters. By our math, hitting the middle of the new full-year target requires sales growth to double to almost 15% over the rest of the year, leaning on the purchase of AdaptHealth's diabetes business closing in the third quarter.
What to watch: second-quarter Other segment revenue, which arrives before the AdaptHealth deal closes. Sales growth below 10% would show that underlying growth in the home-health and nuclear units remains single-digit without new acquisitions.
Medical Products Profit Fell Despite Beating a Low Bar
Global Medical Products and Distribution makes and delivers surgical gloves, drapes and hospital supplies. The division has been under a multi-year turnaround plan to grow its higher-margin Cardinal Health Brand products and cut costs.
First-quarter revenue stayed flat at $3.2 billion, while segment profit dropped 28% from a year ago to $33 million on "unfavorable distribution and foreign exchange impacts partially offset by growth in Cardinal Health Brand". That $33 million beat the roughly $23 million management had told investors to expect for the quarter, but the company did not raise its full-year segment outlook of $200 million to $220 million.
By our math, reaching the $210 million middle of the full-year plan still requires $177 million of profit over the rest of the year — up 58% from last year's $112 million excluding a one-time tariff refund. Meanwhile, the release warns of "risks arising from the conflict with Iran, including the risk that we may not be able to offset or forecast cost increases" alongside tariff uncertainties.
What to watch: second-quarter segment profit against last year's $37 million. A figure above $37 million is needed to show the division has returned to year-over-year growth as planned.
Risks this quarter didn't answer
Three legal and regulatory overhangs received no new financial detail in the first-quarter earnings release.
- Tax disputes with the Internal Revenue Service: potential liabilities of about $1.56 billion from prior audit notices await an update in the quarterly filing's tax footnote.
- Government drug-price rules: Medicare negotiated prices taking effect in January 2027 and potential price controls remain a test for third-quarter distribution fees.
- Federal healthcare investigations: Justice Department inquiries into doctor-practice and group-purchasing deals had no new update, though the company paid $338 million for older legal settlements this quarter.
💲 Other KPIs
Bills owed to drugmakers rose 11.1% from a year ago to $40.94 billion, outpacing the 5.6% rise in customer receivables ($14.54 billion) and the 4.8% rise in inventories ($18.40 billion). Holding onto supplier cash longer than customers take to pay generated $466 million of working-capital cash in the quarter.
Total debt of $8.82 billion minus $5.26 billion of cash left net debt at $3.55 billion by our math, down 20% from $4.44 billion a year ago. The distributor also added $1.0 billion in uncommitted revolving credit lines during the quarter, giving it extra liquidity before $1.89 billion of short-term debt comes due.
Spending on warehouses and equipment rose 45.4% from a year ago to $157 million, or 0.23% of revenue, up from $108 million last year. The company is building out automated distribution centers in Indianapolis, Fort Worth and Sacramento under its $700 million full-year spending plan.
🔮 Guidance
Raised. The new target lifts the middle of the range by $0.40, calling for 18% growth over last year's $10.95 baseline excluding a one-time tariff refund, or 15% over reported $11.26. By our math, that leaves 15% growth against the clean baseline for the rest of the year, down from 28% in Q1 as last year's acquisitions and a third-quarter tax benefit are lapped.
Raised. The middle of the range moved up 1.5 percentage points to 11% growth. After a 17.4% jump in the first quarter, the full-year outlook implies about 9.0% profit growth over the remaining three quarters by our math, reflecting the November anniversary of the Solaris Health purchase.
Raised. Management lifted the target by 2 percentage points at both ends. Because first-quarter profit grew 16.3%, reaching the 18.5% middle of the full-year plan requires profit growth in the nuclear, home-health and logistics units to pick up to 19.2% over the rest of the year by our math.
Raised. The outlook moved up 1 percentage point to a 13% midpoint. Following 7.5% growth in the first quarter, the plan leaves 14.8% sales growth for the rest of the year by our math, aided by the AdaptHealth diabetes acquisition expected to close in the third quarter.
Lowered tax rate (a positive revision to earnings). Management trimmed the expected tax rate by 0.5 percentage points after booking an 18.5% rate in the first quarter, down from 21.9% a year ago.
Lowered share count (a positive revision to per-share earnings). Completing the $500 million share repurchase in the first quarter brought the diluted share count down to 233 million from 239 million a year ago, and the full-year average implies further reduction over the remaining quarters.
❓ Key Questions
How fast did BioPharma Solutions grow in the first quarter?
Management has targeted $1 billion of revenue by fiscal 2028 for BioPharma Solutions, its drugmaker services unit, and previously cited 20%-plus growth. The release gave no figure, and investors need the rate to check if the target is on track.
What is the underlying growth of the Other segment?
Other segment revenue grew 7.5% in Q1, yet the full-year target was raised to 12%–14%. Knowing how much of the second-half step-up comes from the Strive Medical and AdaptHealth diabetes acquisitions would show the true pace of the existing businesses.
How long is the renewed CVS Health distribution agreement?
Cardinal Health signed a binding letter of intent to renew its drug distribution deals with CVS Health, which represents 28% of company revenue. Disclosing the contract length and whether fee rates changed will show how long the renewal protects profit.
Why is medical-products profit still weighted to the second half?
Global Medical Products and Distribution earned $33 million in Q1, beating the ~$23 million verbal target, but the full-year plan stayed at $200–$220 million. Management did not say whether resin costs from the Iran conflict ate into the Q1 beat.